Core Viewpoint - 博济医药 has reported a significant share reduction by a major shareholder, which may impact the company's stock performance and investor sentiment [1] Shareholding Changes - The company received a notice from Fermi No. 13 regarding the reduction of shares, where Fermi No. 13 sold a total of 1.161 million shares between September 12, 2025, and October 17, 2025, representing 0.30% of the total share capital [1] - After this reduction, the controlling shareholder, Wang Tingchun, and his concerted action person, Zhao Lingli, along with Fermi No. 13, collectively hold 142 million shares, accounting for 36.88% of the total share capital [1] - The equity change triggered a 1% integer multiple threshold [1]

Core Viewpoint - The controlling shareholder of Boji Pharmaceutical, Wang Tingchun, along with his concerted parties, plans to reduce their shareholding through a centralized bidding process, impacting the overall shareholding structure of the company [1] Summary by Relevant Sections Shareholding Changes - Wang Tingchun and his concerted parties, Zhao Lingli and Feimi No. 13, will reduce their holdings by 1.161 million shares, which represents 0.30% of the company's total share capital [1] - Due to the exercise of stock options from the 2022 incentive plan, the total share capital of the company has increased, leading to a passive reduction of 0.02% in the shareholding percentage of Wang Tingchun, Feimi No. 13, and Zhao Lingli [1] Current Shareholding Status - After the equity change, the controlling shareholder and his concerted parties will hold a total of 14,226,970 shares, accounting for 36.88% of the company's total share capital [1] - The equity change has reached a threshold of 1% in terms of integer multiples [1] Implementation Status - The reduction plan has not yet been fully implemented [1]

证券代码：300404 证券简称：博济医药 公告编号：2025-078 博济医药科技股份有限公司 关于控股股东及其一致行动人减持股份进展暨权益变动触及 1%的公告 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日在巨 潮资讯网（www.cninfo.com.cn）上披露了《关于控股股东及其一致行动人减持股 份预披露公告》（公告编号：2025-062），公司控股股东、实际控制人王廷春先生 及其一致行动人横琴广金美好基金管理有限公司－广金美好费米十三号私募证 券投资基金（以下简称"费米十三号"）计划在上述公告披露之日起 15 个交易日 后的 3 个月内（即 2025 年 9 月 12 日至 2025 年 12 月 11 日），以大宗交易或集中 竞价的方式合计减持本公司股份不超过 11,486,500 股（占公司剔除回购专用证券 账户中股份数量后总股本的 3.00%）。 近日，公司收到费米十三号出具的《关于股份减持进展的告知函》，获悉费 米十三号在 2025 年 9 月 12 日至 2025 年 10 月 17 日期间，通过集中竞价减持公 司股票共计 1,161,000 股，占公司总股 ...

证券日报网讯 10月14日晚间，博济医药发布公告称，公司于2025年8月25日召开第五届董事会第十六次 会议以及于2025年9月12日召开2025年第一次临时股东大会，审议通过了《关于变更公司注册资本及修 订的议案》，同意公司变更注册资本，并根据相关规定及公司实际情况对《公司章程》中相关内容进行 修订。近日，公司完成了上述事项的工商变更登记及备案手续，取得了广州市市场监督管理局换发的 《营业执照》。 （编辑 任世碧） ...

证券代码：300404 证券简称：博济医药 公告编号：2025-077 博济医药科技股份有限公司 关于公司完成工商变更登记及备案的公告 统一社会信用代码：91440101743555883K 名称：博济医药科技股份有限公司 类型：其他股份有限公司（上市） 住所：广州黄埔区科学城南翔一路 62 号（二、三、四、五）栋 法定代表人：王廷春 注册资本：叁亿捌仟伍佰伍拾伍万陆仟零柒拾捌元（人民币） 成立日期：2002 年 9 月 29 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召开 第五届董事会第十六次会议以及于 2025 年 9 月 12 日召开 2025 年第一次临时股 东大会，审议通过了《关于变更公司注册资本及修订<公司章程>的议案》，同意 公司变更注册资本，并根据相关规定及公司实际情况对《公司章程》中相关内容 进行修订。具体内容详见公司于 2025 年 8 月 27 日、2025 年 9 月 13 日披露在巨 潮资讯网（www.cninfo.com.cn）上的相关公告。 近 ...

Core Viewpoint - Shanghai Xiaofang Pharmaceutical Co., Ltd. has signed a technical entrustment contract with Boji Pharmaceutical Technology Co., Ltd. to assist in the clinical research and registration of the new traditional Chinese medicine "Compound Cèbǎi Tincture" for hair loss treatment, marking a significant step in the company's innovation drug strategy [2][12]. Group 1: Transaction Overview - The transaction does not constitute a major asset restructuring as defined by the relevant regulations and does not involve related party transactions [2]. - The collaboration aims to complete the clinical trials and market registration of the new drug, with no significant impact on the company's operating results for the current year [3][12]. Group 2: Partner Information - Boji Pharmaceutical, established in 2002 and listed on the Shenzhen Stock Exchange in 2015, specializes in providing comprehensive outsourcing services for drug and medical device development [4]. - The company has a registered capital of 381.99 million RMB and has a strong track record in traditional Chinese medicine research and development [4]. Group 3: Project Details - The project involves the development of the traditional Chinese medicine "Compound Cèbǎi Tincture" through a commissioned development approach [5]. - Boji Pharmaceutical is responsible for designing and executing the research plans, conducting clinical trial monitoring, and assisting in the registration application [7]. Group 4: Contractual Terms - The intellectual property generated from the project will belong to Shanghai Xiaofang Pharmaceutical, including clinical trial data and research reports [6]. - The contract will be effective upon signing and will remain valid until the new drug application (NDA) is approved [9]. Group 5: Impact on the Company - The collaboration is expected to leverage the strengths of both companies, enhancing the efficiency and success rate of the product's development, thereby laying a solid foundation for future applications and market entry [12].

Core Viewpoint - The collaboration between Xiao Fang Pharmaceutical and Boji Pharmaceutical marks a significant step in the development of innovative drugs, particularly in the clinical research and registration of a new traditional Chinese medicine product [1] Group 1: Partnership Details - Xiao Fang Pharmaceutical has signed a "Technical Entrustment (Development) Contract" with Boji Pharmaceutical to assist in the clinical research and registration of a Class 1 traditional Chinese medicine compound [1] - This partnership is based on a shared strategic development vision, indicating a strong alliance between the two companies [1] Group 2: Strategic Implications - The collaboration is expected to leverage Boji Pharmaceutical's strengths in research and development, technical expertise, and clinical resources, enhancing the efficiency and success rate of the product's development [1] - The partnership aims to establish a solid foundation for the subsequent application and market launch of the product [1]

Core Viewpoint - The company, Xiao Fang Pharmaceutical, has signed a technical entrustment contract with Boji Pharmaceutical to assist in the clinical research and registration of a new traditional Chinese medicine, Compound Cypraea Tincture, which is classified as a Class 1 new drug [1] Group 1 - The collaboration aims to facilitate the completion of clinical trials and the subsequent market launch of the new drug [1] - This transaction does not constitute a major asset restructuring or a related party transaction [1] - The agreement is not expected to have a significant impact on the company's operating results for the current fiscal year [1]

Core Viewpoint - The company, Boji Pharmaceutical, has received a patent from the National Intellectual Property Administration for a method to measure gallic acid in berberine [2] Group 1 - The patent is titled "A method for determining gallic acid in berberine" [2] - The announcement was made on the evening of September 19 [2]

Core Insights - The company held an investor meeting on September 19, discussing its ongoing projects and financial performance [1][2] - The "Semaglutide Injection" project with Novartis is currently in the Phase III clinical trial follow-up stage, which is expected to positively impact future operating performance [1] - The company focuses on providing CRO services primarily for innovative drugs across various therapeutic areas [1] Group 1: Project Development - The company is developing several innovative drugs, including a traditional Chinese medicine for chronic heart failure and a small molecule new drug for high uric acid levels [2] - Currently, there are no self-developed projects in the oncology field, but the company provides clinical research services for multiple oncology drugs [2] - The timeline for research and development is influenced by project progress and the sponsor's investment [2] Group 2: Financial Management - The company emphasizes improving operational quality as the core of its market value management [2] - Idle cash is primarily invested in low-risk, high-liquidity financial products rather than high-risk securities or derivatives [2] - For the first half of 2025, the company's R&D investment was approximately 23.2 million, accounting for about 6% of revenue, which is higher than the net profit for the same period [2]